CMS Open Payments · Program Year 2024
MIM Software Inc.
MIM Software Inc. reported $67,143.50 across General Payments, Research, and Ownership to 50 physicians and teaching hospitals across 50 transactions.
- $67.1K
- All-tracks total
- 50
- Transactions
- 50
- Recipients
- −$15.8K
- General Payments vs PY2023
MIM Software Inc. reported $67,143.50 across all CMS Open Payments tracks (General + Research + Ownership) to 50 physicians and teaching hospitals in Program Year 2024 - ranking #1277 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $67,143.50, averaging $1.3K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mim-software-inc MIM Software Inc.
$67.1K · #1277/1,925 · 0.0% industry · PY2024
- TOT $67.1K
- RANK #1277
- SHARE 0.0%
- TXN 50
- RCP 50
- CAT 4
- GEN $67.1K
- ΔGEN −$15.8K
- TOP1 21.8%
- PY 2024
Volume peers
Nearest volume peer: Icometrix NV ($67.0K)
MIM Software Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
MIM Software Inc.'s CMS-reported General Payments decreased by $15.8K (−19.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MIM SOFTWARE INC.PY2023: MIM SOFTWARE INC.PY2024: MIM Software Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $82,984.50
- PY2024
- $67,143.50
What the Data Shows for MIM Software Inc.
Averaging $1.3K per transaction and $1.3K per recipient, MIM Software Inc.'s Program Year 2024 total comes to $67,143.50 across 50 transactions and 50 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1277 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 4 general-payment categories charted below, "Long-Term Medical Supply or Device Loan" is the largest at $34.1K across 3 transactions, 50.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Long-Term Medical Supply or Device Loan" leads MIM Software Inc.'s 4-category general-payment breakdown at $34.1K, 50.8% of the reported total.
MIM Software Inc. reports 4 general-payment categories - the top three are Long-Term Medical Supply or Device Loan (50.8%), Consulting Fee (39.2%), and Compensation for Services Other Than Consulting (8.3%). The remaining 1 category make up 1.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How MIM Software Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Long-Term Medical Supply or Device Loan | $34.1K | 3 | 50.8% |
| Consulting Fee | $26.3K | 15 | 39.2% |
| Compensation for Services Other Than Consulting | $5.6K | 7 | 8.3% |
| Food and Beverage | $1.1K | 25 | 1.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $56,041.50 (83.5%) of $67,143.50 in this company's General Payments records across 38 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for MIM Software Inc.
The five named recipients with the highest reported General Payments from this company
- 1
The Johns Hopkins Hospital
$14,631.00 across 1 reported transactions
- 2
Ut Md Anderson Cancer Center
$12,820.00 across 1 reported transactions
- 3
Jean-Pierre Obeid
$12,323.50 across 1 reported transactions
- 4
Hubert Jean Vesselle
$9,600.00 across 12 reported transactions
- 5
Uci Medical Center
$6,667.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as MIM Software Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about MIM Software Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with MIM Software Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Momentis Surgical Inc.
Immunitybio, Inc.
Shimadzu Precision Instruments, Inc.
Cambridge Interventional LLC
Pathway Medical Partners, LLC
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.